Medicine Tailored to the Tumor
Personalized cancer vaccines represent one of oncology most exciting frontiers: using the same mRNA technology that produced COVID vaccines to train a patient immune system against the unique mutations in their specific tumor. Because every cancer carries a distinct set of mutations, these vaccines are custom-manufactured for each individual, teaching immune cells to recognize the neoantigens — mutated proteins — that mark their particular cancer.
How They Work
The process begins by sequencing a patient tumor to identify mutations that produce abnormal proteins not found in healthy cells. A vaccine is then designed to present these neoantigens to the immune system, prompting it to recognize and attack cells displaying them. Often combined with immunotherapy that releases the brakes on immune cells, this approach aims to mount a targeted, personalized assault on residual cancer and reduce the risk of recurrence after primary treatment.
Early Promise
Trials in melanoma and pancreatic cancer, among others, have shown encouraging results in reducing recurrence when personalized vaccines are combined with immunotherapy. The approach is still investigational and manufacturing is complex, but the concept of treatment tailored to each patient tumor represents a profound shift toward precision oncology. As the technology matures, it may become a standard adjunct to surgery and other therapies. Research facilities can source lab supplies and diagnostic equipment from our catalog.
